We are pleased to announce that we have recently signed a USD 250 million contract with Artemis DNA. Artemis DNA is a leading US-based diagnostic laboratory company providing proprietary next generation sequencing (NGS) gene tests and diagnostic laboratory services for a variety of medical specialities, including cardiology, oncology, immunology, neurology, reproductive medicine and pharmacogenomics. Under… Continue reading MARKET ENTRY IN THE USA THANKS TO AGREEMENT WITH ARTEMIS DNA
After TrucheckTM Breast, a blood test for the detection of early-stage breast cancer, has already received “Breakthrough Device Designation” from the FDA, this has now also been announced for Trublood Prostate. Both tests are CE-certified and already available in Europe. Trublood Prostate is the first blood test that can detect early-stage prostate cancer with high… Continue reading Screeening test for the early detection of prostate cancer also receives “Breakthrough Device Designation” from the FDA
The US Food and Drug Administration (FDA) has granted Breakthrough Device Designation to our CE-certified test TrucheckTM Breast, a blood test for the detection of early-stage breast cancers. Breakthrough Designation is awarded by the US FDA for innovative devices/analyses that have the potential to ensure more effective diagnosis of life-threatening diseases such as cancer. The… Continue reading US FDA grants ‘Breakthrough Designation’ for our blood test used for early detection of breast cancer
In September 2021, Dr. Stefan Schuster gave a talk on the results interpretation of exacta to 180 oncologists at the MKOT Symposium. Videos and pictures of the event can be found here: MKOT Symposium 2021 #personalizedmedicine #liquidbiopsy #oncology #cancer #diagnostics
Datar Cancer Genetics has so far focused on comprehensive molecular profiling of cancers, especially in advanced solid tumours. Due to the extensive clinical trials in recent years in the field of liquid biopsy with over 40,000 patients, it is now also possible for us to provide a screening solution for solid tumours. Click here for… Continue reading DCG expands Product Portfolio to Screening-Test
We are excited to be partnering with Iylon Precision Oncology. The US-based company works with experts from around the world to create a personalised, evidence-based and optimised treatment recommendation for each patient. In future, they will also use our innovative product services based on molecular and cell analyses for their recommendations. Prof Sendurai Mani, co-founder… Continue reading Our cooperation with Iylon Precision Oncology
